Related Experiment Video
Updated: Jun 28, 2025
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways
1Mayo Clinic, Jacksonville, FL.
Abstract:
The advent of immune checkpoint blockade therapy has revolutionized cancer treatments and is partly responsible for the significant decline in cancer-related mortality observed during the last decade. Immune checkpoint inhibitors, such as anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1), have demonstrated remarkable clinical successes in a subset of cancer patients. However, a considerable proportion of patients remain refractory to immune checkpoint blockade, prompting the exploration of mechanisms of treatment resistance. Whereas much emphasis has been placed on the role of PD-L1 and PD-1 in regulating the activity of tumor-infiltrating T cells, recent studies have now shown that this immunoregulatory axis also directly regulates myeloid cell activity in the tumor microenvironment including tumor-infiltrating dendritic cells. In this review, I discuss the most recent advances in the understanding of how PD-1, PD-L1, and programmed cell death ligand 2 regulate the function of tumor-infiltrating dendritic cells, emphasizing the need for further mechanistic studies that could facilitate the development of novel combination immunotherapies for improved cancer patient benefit.
Insights
Immune checkpoint inhibitors like PD-1/PD-L1 therapies show promise in cancer treatment but not all patients respond. This review explores how these pathways regulate dendritic cells, suggesting new combination therapies for better outcomes.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Immune checkpoint blockade therapy, including anti-PD-1/PD-L1, has transformed cancer treatment, reducing mortality.
- Despite successes, many patients do not respond to these therapies, necessitating research into resistance mechanisms.
Approach:
- This review synthesizes recent findings on the role of the PD-1/PD-L1 axis in regulating myeloid cell activity within the tumor microenvironment.
- Focus is placed on the direct impact of PD-1, PD-L1, and PD-L2 on the function of tumor-infiltrating dendritic cells.
Key Points:
- The PD-1/PD-L1 immunoregulatory axis extends beyond T cell regulation to directly influence myeloid cells, particularly dendritic cells.
- Understanding these interactions is crucial for deciphering mechanisms of resistance to current immunotherapies.
Conclusions:
- Further mechanistic studies are needed to elucidate the precise roles of PD-1, PD-L1, and PD-L2 in dendritic cell function.
- This knowledge can guide the development of novel combination immunotherapies to enhance treatment efficacy and benefit more cancer patients.
Related Concept Videos
01:17The Extrinsic Apoptotic Pathway
01:31The Intrinsic Apoptotic Pathway
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:23Abnormal Proliferation
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...